Table 2.
Histopathological and clinical parameters of patients subjected to paired analysis of galectin-1 and galectin-3 expression in tumors vs. adjacent normal kidney tissue
| Patients for paired analysis | No. | % |
|---|---|---|
|
Total |
75 |
100% |
|
Patients |
|
|
| Age (mean; ±SD) |
67 (11.8) |
|
| Male |
46 |
61.3% |
| Female |
29 |
38.7% |
|
Histology |
|
|
| Clear cell |
58 |
77.3% |
| Papillary |
12 |
16% |
| Chromophobe |
4 |
5.3% |
| Other/notclassified |
1 |
1.3% |
|
Stage |
|
|
| NA |
3 |
4% |
| pT1 |
4 |
5.3% |
| pT1a |
24 |
32% |
| pT1b |
14 |
18.7% |
| pT2 |
4 |
5.3% |
| pT3 |
1 |
1.3% |
| pT3a |
6 |
8% |
| pT3b |
19 |
25.3% |
| pT4 |
0 |
0% |
|
Grade |
|
|
| G1 |
9 |
12% |
| G1-2 |
11 |
14.7% |
| G2 |
40 |
53.3% |
| G2-3 |
6 |
8% |
| G3 |
9 |
12% |
|
LN metastasis* |
7 |
9.3% |
|
Visceral metastasis* |
19 |
25.3% |
|
locally advanced/metastatic |
|
|
| disease (pT3>4 and/or N/M+) | 36 | 48% |
∗At time of surgical intervention. SD = standard deviation, LN = lymph node, N+ = lymph node metastasis, M+ = organ metastasis.